- Home
- KALA vs BOLT Comparison
KALA vs BOLT Comparison
Compare KALA & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- BOLT
- Stock Information
- Founded
- KALA 2009
- BOLT 2015
- Country
- KALA United States
- BOLT United States
- Employees
- KALA N/A
- BOLT N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- BOLT Health Care
- Exchange
- KALA Nasdaq
- BOLT Nasdaq
- Market Cap
- KALA 26.2M
- BOLT 16.8M
- IPO Year
- KALA 2017
- BOLT 2021
- Fundamental
- Price
- KALA $5.10
- BOLT N/A
- Analyst Decision
- KALA Strong Buy
- BOLT Buy
- Analyst Count
- KALA 3
- BOLT 3
- Target Price
- KALA $14.00
- BOLT $50.00
- AVG Volume (30 Days)
- KALA 71.3K
- BOLT 25.1K
- Earning Date
- KALA 08-05-2025
- BOLT 08-12-2025
- Dividend Yield
- KALA N/A
- BOLT N/A
- EPS Growth
- KALA N/A
- BOLT N/A
- EPS
- KALA N/A
- BOLT N/A
- Revenue
- KALA N/A
- BOLT $3,638,000.00
- Revenue This Year
- KALA N/A
- BOLT N/A
- Revenue Next Year
- KALA N/A
- BOLT $24.14
- P/E Ratio
- KALA N/A
- BOLT N/A
- Revenue Growth
- KALA N/A
- BOLT N/A
- 52 Week Low
- KALA $2.92
- BOLT $5.20
- 52 Week High
- KALA $11.20
- BOLT $15.60
- Technical
- Relative Strength Index (RSI)
- KALA 62.32
- BOLT 47.22
- Support Level
- KALA $4.36
- BOLT $5.52
- Resistance Level
- KALA $5.90
- BOLT $6.21
- Average True Range (ATR)
- KALA 0.50
- BOLT 0.32
- MACD
- KALA 0.07
- BOLT 0.05
- Stochastic Oscillator
- KALA 61.50
- BOLT 60.22
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.